Yeah that's why I mentioned it's Open Access Peer review. I'm surprised they didn't reference CS1 or related articles.
I would've thought that the keywords: FTO Inhibition, cancer and CS1/Bisantrene/Zantrene all go hand-in-hand.
Regardless, any news (good or bad) on FTO inhibition is helpful for RAC, and the studies here further highlight Mason's post in the previous page about FTO inhibition effects on cancers
Pillar 1 - FTO (new thread), page-1503
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.050(3.17%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.59 | $1.51 | $174.6K | 113.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2372 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 141 | 1 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |